Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Sara A. Väyrynen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1768-0471; OpenAlex author ID A5054541682. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper

Papers 8

  1. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  2. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-22-1125↗
  3. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  4. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  5. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  6. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  7. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  8. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andressa Dias Costa · 8 shared papers, 2019–2023 · strength 0.71
  2. Brian Matthew Wolpin · 8 shared papers, 2019–2023 · strength 0.71
  3. Jonathan Andrew Nowak · 8 shared papers, 2019–2023 · strength 0.71
  4. Thomas E. Clancy · 5 shared papers, 2021–2023 · strength 0.48
  5. Douglas Adam Rubinson · 5 shared papers, 2021–2023 · strength 0.48
  6. Albert C. Koong · 5 shared papers, 2019–2023 · strength 0.45
  7. Richard Francis Dunne · 5 shared papers, 2019–2023 · strength 0.45
  8. Daniel Tandel Chang · 5 shared papers, 2019–2023 · strength 0.45
  9. Aram F. Hezel · 5 shared papers, 2019–2023 · strength 0.45
  10. Chen Yuan · 4 shared papers, 2021–2023 · strength 0.40
  11. Vicente Morales‐Oyarvide · 4 shared papers, 2021–2023 · strength 0.40
  12. Hannah L. Williams · 4 shared papers, 2021–2023 · strength 0.39
  13. Andrew J. Aguirre · 4 shared papers, 2021–2023 · strength 0.39
  14. David C. Linehan · 3 shared papers, 2021–2023 · strength 0.31
  15. Jiping Wang · 3 shared papers, 2021–2023 · strength 0.31
  16. Margaret M. Kozak · 3 shared papers, 2021–2023 · strength 0.31
  17. Kimberly J. Perez · 3 shared papers, 2021–2023 · strength 0.30
  18. James M. Cleary · 3 shared papers, 2021–2023 · strength 0.30
  19. Lisa M. Coussens · 3 shared papers, 2021 · strength 0.27
  20. Charles S. Fuchs · 3 shared papers, 2019–2021 · strength 0.23
  21. Tyler Jacks · 3 shared papers, 2019–2021 · strength 0.22
  22. Harshabad Singh · 2 shared papers, 2022–2023 · strength 0.22
  23. Joseph Douglas Mancias · 2 shared papers, 2022–2023 · strength 0.22
  24. Alex K. Shalek · 2 shared papers, 2021–2023 · strength 0.19
  25. Srivatsan Raghavan · 2 shared papers, 2021–2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.